Antiviral Mechanism

Antiviral Mechanism designates the specific biochemical or biological process through which antiviral compounds interfere with viral replication cycles, including blocking viral entry, inhibiting viral polymerases, protease cleavage, integrase function, or assembly processes critical for producing infectious viral progeny.

The pharmaceutical industry develops antivirals targeting diverse mechanisms across pathogen life cycles. Neuraminidase inhibitors prevent influenza release from infected cells. HIV reverse transcriptase inhibitors block viral genome replication. Protease inhibitors prevent polyprotein processing into functional viral proteins. Integrase inhibitors block HIV DNA integration into host chromosomes. Entry inhibitors prevent viral binding to host receptors. Broadly acting antivirals targeting conserved host factors support pan-viral approaches. Combination therapy targeting multiple mechanisms simultaneously reduces resistance emergence. Resistance mechanism surveillance monitors for viral evolution reducing drug susceptibility. As emerging viral threats require rapid antiviral development, platform technologies enabling rapid mechanism-based drug design continue advancing alongside stockpiled broad-spectrum antivirals supporting pandemic preparedness.